{"doi":"10.1128/aac.01258-23","title":"<i>In vitro</i> activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant <i>Acinetobacter baumannii</i> collected in U.S. hospitals","abstract":"ABSTRACT The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC 50 /MIC 90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.","journal":"Antimicrobial Agents and Chemotherapy","year":2024,"id":421500,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":29,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9503,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":282880,"name":"Christi L. McElheny","orcid":"0000-0003-0967-504X","position":1,"is_corresponding":false},{"id":650673,"name":"Erin L. Fowler","orcid":null,"position":2,"is_corresponding":false},{"id":234482,"name":"Eric Cober","orcid":null,"position":3,"is_corresponding":false},{"id":618259,"name":"Erica Herc","orcid":"0000-0002-9069-6659","position":4,"is_corresponding":false},{"id":232742,"name":"César A. Arias","orcid":"0000-0001-9054-9774","position":5,"is_corresponding":false},{"id":232758,"name":"Carol Hill","orcid":"0000-0001-6254-6867","position":6,"is_corresponding":false},{"id":619589,"name":"Keri Baum","orcid":null,"position":7,"is_corresponding":false},{"id":32929,"name":"Vance G. Fowler","orcid":"0000-0002-8048-0897","position":8,"is_corresponding":false},{"id":232760,"name":"Henry F. Chambers","orcid":"0000-0001-5317-4491","position":9,"is_corresponding":false},{"id":418597,"name":"Kerryl E. Greenwood‐Quaintance","orcid":"0000-0003-3760-4310","position":10,"is_corresponding":false},{"id":232756,"name":"Robin Patel","orcid":"0000-0001-6344-4141","position":11,"is_corresponding":false},{"id":232741,"name":"David van Duin","orcid":"0000-0003-4784-3227","position":12,"is_corresponding":false},{"id":232761,"name":"Robert A. Bonomo","orcid":"0000-0002-3299-894X","position":13,"is_corresponding":false},{"id":232746,"name":"Yohei Doi","orcid":"0000-0002-9620-2525","position":14,"is_corresponding":false},{"id":282877,"name":"Alina Iovleva","orcid":"0000-0002-3599-7221","position":0,"is_corresponding":true}],"reference_count":9,"raw_metadata":null,"created_at":"2026-07-19T01:57:41.370244Z","pmid":"38289078","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}